Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
PAK6 is a member of a family of p21-stimulated serine/threonine protein kinases, which contain an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain. These kinases function in a number of cellular processes, including cytoskeleton rearrangement, apoptosis, and the mitogen-activated protein (MAP) kinase signaling pathway. The protein encoded by this gene interacts with androgen receptor (AR) and translocates to the nucleus, where it is involved in transcriptional regulation. Changes in expression of this gene have been linked to prostate cancer. Alternative splicing results in multiple transcript variants.
|Gene Name:||p21 protein (Cdc42/Rac)-activated kinase 6|
|Family/Subfamily:||Protein Kinase , PAK (STE20)|
|Synonyms:||PAK6, PAK5, p21-activated kinase 6, p21-activated protein kinase 6, PAK-5, PAK-6, p21(CDKN1A)-activated kinase 6|
|Target Sequences:||NM_020168 NP_064553.1 Q9NQU5|
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.